Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Spira 80-marker panel plus clinical factors

Spira 80-marker panel plus clinical factors

Basics

Attributes

QA State: Curated
Short Name:

This clinicogenomic model incorporates the gene expression pattern of histologcially normal large airway epithelial cells collected at time of bronchoscopy (see "Spira 80-marker panel for lung cancer) with clinical parameters about lung cancer risk.

Panel Details

No member markers defined for this panel.

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: One
QA State: Curated

The Spira 80-marker panel for lung cancer biomarker was developed by using the gene expression patterns obtained from cytologically normal large airway epithelial cells from smokers undergoing bronchoscopy for suspiction of lung cancer. The results from the bronchosopy are 100% specific for lung cancer, but has a limited sensitivity of 30-80% depending ont he stage and location of the cancer. Therefore, difficult decisions must be made regarding care and treatment of patients with potentially early-stage, treatable, curable cancers. By adding the clinical factors to the 80-marker panel, the predictive nature of the model has been improved.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

No associated resources found.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement